scholarly journals High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

2017 ◽  
Vol 19 (1) ◽  
Author(s):  
Tsutomu Takeuchi ◽  
Nobuyuki Miyasaka ◽  
Takashi Inui ◽  
Toshiro Yano ◽  
Toru Yoshinari ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Drug Levels ◽  
Post Hoc Analysis ◽  
Clinical Responses ◽  
Post Hoc

scholarly journals Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib

2021 ◽  
Author(s):  
Janet E. Pope ◽  
Yvonne C. Lee ◽  
Jeffrey R. Curtis ◽  
Daojun Mo ◽  
Li Xie ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pain Reduction ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Vibeke Strand ◽  
Jeffrey Kaine ◽  
Rieke Alten ◽  
Gene Wallenstein ◽  
Annette Diehl ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Physical Function ◽  
Global Assessment ◽  
Janus Kinase ◽  
Patient Global Assessment ◽  
Normative Values ◽  
Post Hoc Analysis ◽  
Patient Reported ◽  
Post Hoc

Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined the degree to which Patient Global Assessment of Disease Activity (PtGA) was driven by patient-reported assessments of pain (Pain), physical function, and fatigue in patients receiving tofacitinib 5 mg twice daily or placebo, each with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods This post hoc analysis used data pooled from three randomized controlled trials in csDMARD-inadequate responder (csDMARD-IR) patients (ORAL Scan: NCT00847613; ORAL Standard: NCT00853385; ORAL Sync: NCT00856544). Using subgroup analysis from 2 × 2 tables, associations between PtGA and Pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at month 3 were evaluated using Pearson’s Phi correlation coefficients. To support the main analysis, associations between select patient-reported outcomes (PROs) were also evaluated in csDMARD-naïve (ORAL Start; NCT01039688) and biologic (b)DMARD-IR (ORAL Step; NCT00960440) patients. Results Across csDMARD-IR treatment groups, low disease activity (defined as PtGA ≤ 20 mm), and moderate (≥ 30%) and substantial (≥ 50%) improvements from baseline in PtGA were associated with mild Pain (Visual Analog Scale score ≤ 20 mm), and moderate (≥ 30%) and substantial (≥ 50%) improvements from baseline in Pain; lack of Pain improvement was associated with little/no improvement in PtGA. In contrast, large proportions of csDMARD-IR patients who reported PtGA improvements did not report HAQ-DI or FACIT-F scores ≥ normative values (≤ 0.25 and ≥ 43.5, respectively) or changes in HAQ-DI or FACIT-F scores ≥ minimum clinically important difference (≥ 0.22 and ≥ 4.0, respectively). Generally, PtGA and Pain outcomes were moderately-to-strongly correlated at month 3 in csDMARD-IR patients, with weaker correlations evident between PtGA and HAQ-DI/FACIT-F outcomes. Similar findings were generally evident in csDMARD-naïve and bDMARD-IR patients. Conclusions This analysis supports the role of Pain as a key driver of PtGA in RA; physical function and fatigue play lesser roles in patients’ perceptions of disease activity. These findings corroborate the importance of improved PROs and attainment of low symptom states for optimizing patient care. Trial registration Clinicaltrials.gov: NCT00847613 (registered: February 19, 2009); NCT00853385 (registered: March 2, 2009); NCT00856544 (registered: March 5, 2009); NCT01039688 (registered: December 25, 2009); NCT00960440 (registered: August 17, 2009)

scholarly journals AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS

2019 ◽  
Author(s):  
Daniel Aletaha ◽  
Juan Jose Gomez-Reino ◽  
Gerd Rdiger Burmester ◽  
Ronald van Vollenhoven ◽  
Jose Luis Rivas ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

2018 ◽  
Vol 20 (1) ◽  
Author(s):  
Nadia M. T. Roodenrijs ◽  
Maria J. H. de Hair ◽  
Gill Wheater ◽  
Mohsen Elshahaly ◽  
Janneke Tekstra ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Studies ◽  
Disease Activity ◽  
Disease Activity Score ◽  
Activity Score ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document